Atco Laboratories Limited
Pharmaceutical manufacturer · Karachi · Pakistan
Long-established Pakistan pharmaceutical manufacturer developing, formulating and marketing generic medicines from a cGMP-compliant Karachi facility.
What is sourced, and how recent is it?
Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.
Company profile
- Company type
- Pharmaceutical manufacturer
- Address
- B-18, S.I.T.E., Karachi-75700, Pakistan · 75700
- Website
- atcolab.com ↗
- Phone
- +92 21 111 111 645
- info@atcolab.com
- Official contact
- Contact page ↗
- Corporate source details checked
- 16 Aug 2026
- Corporate profile completeness
- 100%
Company location
A sourced company location is recorded. Use the map link below for directions.
Portfolio at a glance
RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.
PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.
IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.
Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.
Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.
Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.
How complete is this profile?
Downloadable company intelligence charts
Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.
Therapeutic Portfolio Mix
Shows where the company portfolio is concentrated across broad therapeutic areas.
Portfolio distribution, not sales or market-share data.
Dosage Form Portfolio
Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.
Counts are product presentations, not production or sales volumes.
Equivalent Price Position
Shows whether safely comparable products are below, near or above the peer median unit price.
This is price-position intelligence, not sales, demand or market-share data.
Closest Portfolio Competitors
Highlights other manufacturers with the greatest generic overlap with this company portfolio.
Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.
Therapeutic areas
High-level clinical areas represented by this company’s current MedInfoBase portfolio.
Drug classes
More specific classes derived from the canonical generic and preserved curated classifications.
Dosage forms
How MedInfoBase classifies the portfolio
MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.
Deepest brand families
Unit-price positioning vs equivalent products
How MedInfoBase calculates price position
Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.
Portfolio overlap
Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.
Observed database signals
These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.
Medicine portfolio
This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.
| Brand | Generic | Strength | Form | Pack | Registration | Source-listed price | Unit price | Price position |
|---|---|---|---|---|---|---|---|---|
| Gentacil | Gentamicin | 40 mg/mL | Injection | 3's x 1 ml | 013959 | PKR 60.01 | PKR 20.00/mL | 21% below median |
| Gentacil | Gentamicin | 80 mg/2 mL | Injection | 10's x 2ml | 015835 | PKR 437.36 | PKR 21.87/mL | 40% above median |
| Intaxel | Paclitaxel | 30 mg (6 mg/mL) | Injection | 1 vial | 044881 | PKR 6,122.53 | PKR 6,122.53/vial/unit | No comparator |
| Intaxel | Paclitaxel | 100 mg (6 mg/mL) | Injection | 1 vial | 044882 | PKR 18,587.73 | PKR 18,587.73/vial/unit | No comparator |
| Intaxel | Paclitaxel | 150 mg (6 mg/mL) | Injection | 1 vial | 045707 | PKR 25,196.71 | PKR 25,196.71/vial/unit | No comparator |
| Intaxel | Paclitaxel | 260 mg (6 mg/mL) | Injection | 1 vial | 045708 | PKR 35,729.76 | PKR 35,729.76/vial/unit | No comparator |
| Intaxel | Paclitaxel | 300 mg (6 mg/mL) | Injection | 1 vial | 045709 | PKR 41,977.31 | PKR 41,977.31/vial/unit | No comparator |
| IPNEB INHALATION | Ipratropium bromide | 0.25 mg/mL | Solution | 20ml | 053356 | PKR 194.13 | PKR 9.71/mL | No comparator |
| IVERMITE | Ivermectin | 6 mg | Tablet | 10'S | 061339 | PKR 595.62 | PKR 59.56/tablet | 9% above median |
| LAME | Lisinopril | 5 mg | Tablet | 30's | 026225 | PKR 305.48 | PKR 10.18/tablet | 38% above median |
| LAME | Lisinopril | 10 mg | Tablet | 30's | 026226 | PKR 587.46 | PKR 19.58/tablet | 17% above median |
| LAMORETIC | Lisinopril + Hydrochlorothiazide | 20 mg + 12.50 mg | Tablet | 28's | 039374 | PKR 926.92 | PKR 33.10/tablet | 9% below median |
| LEISHMAFOS | Miltefosine | 50 mg | Capsule | 56's | 088226 | PKR 31,063.99 | PKR 554.71/capsule | Near median |
| LOPLUS | Losartan + Hydrochlorothiazide | 50 mg + 12.50 mg | Tablet | 20's | 039375 | PKR 426.52 | PKR 21.33/tablet | 13% below median |
| LOSTRESS | Losartan | 25 mg | Tablet | 2 x 10's | 031999 | PKR 203.12 | PKR 10.16/tablet | 11% below median |
| MEGLU | MEGLUMINE ANTIMONIATE | 1.5 g/5 mL | Injection | 5's x 5ml | 082111 | PKR 564.91 | PKR 22.60/mL | No comparator |
| MESKAZOLE | Mebendazole | 100 MG | Tablet | 60's | 100272 | PKR 457.51 | PKR 7.63/tablet | 14% above median |
| METSULIN | Metformin | 850 mg | Tablet | 10x10's | 009061 | PKR 257.31 | PKR 2.57/tablet | 41% below median |
| METSULIN | Metformin | 500 mg | Tablet | 5 x 10's | 037953 | PKR 167.80 | PKR 3.36/tablet | 24% above median |
| MICRONA | Miconazole | 1 % | Cream | 10GM | 014208 | PKR 94.18 | PKR 9.42/g | No comparator |
| Minirin | Desmopressin acetate | 10 mcg/dose | Nasal spray | 1'S | 016112 | PKR 6,993.88 | PKR 6,993.88/unit | No comparator |
| OSEFLU | Oseltamivir | 75 mg | Capsule | 10's | 042126 | PKR 2,142.50 | PKR 214.25/capsule | 78% above median |
| OSMOLAR ORS | Sodium chloride + Potassium chloride + Trisodium citrate dihydrate + Glucose anhydrous | 1.3 g + 0.75 g + 1.45 g + 6.75 g | Sachet | 20's | 045416 | PKR 428.50 | PKR 21.43/sachet | 18% below median |
| OXCIN | Moxifloxacin | 0.5 % | Ophthalmic solution | 5ml | 055601 | PKR 638.87 | PKR 127.77/mL | No comparator |
| PIPRA | Dihydroartemisinin + Piperaquine | 15 mg + 120 mg | Sachet | 16's | 073873 | PKR 800.26 | PKR 50.02/sachet | 5% above median |
| PIPRA | Dihydroartemisinin + Piperaquine | 40 mg + 320 mg | Tablet | 8's | 073874 | PKR 680.22 | PKR 85.03/tablet | Near median |
| POXVIR | Aciclovir | 200 MG/5 mL | Oral suspension | 60ml | 091254 | PKR 310.64 | PKR 5.18/mL | Near median |
| PPI-ONE | Omeprazole | 20 mg | Capsule | 14's | 050624 | PKR 265.90 | PKR 18.99/capsule | Near median |
| PRIMOX | Sulfamethoxazole + Trimethoprim | 400 mg + 80 mg / 10 mL | Suspension | 50ml | 005997 | PKR 55.39 | PKR 1.11/mL | No comparator |
| PRIMOX | Sulfamethoxazole + Trimethoprim | 400 mg + 80 mg | Tablet | 200's | 005998 | PKR 268.49 | PKR 1.34/tablet | 52% below median |
| Primox DS | Sulfamethoxazole + Trimethoprim | 800 mg + 160 mg | Tablet | 100's | 007385 | PKR 290.86 | PKR 2.91/tablet | 69% below median |
| PRO-EPUTIN | Fosphenytoin sodium | 50 mg | Injection | 2ml | 053358 | PKR 276.99 | PKR 138.50/mL | 7% above median |
| PRO-EPUTIN | Fosphenytoin sodium | 50 mg | Injection | 10ml | 053358 | PKR 1,292.61 | PKR 129.26/mL | 7% below median |
| PROLOX | Ciprofloxacin | 3 mg/mL | Ophthalmic drops | 5ml | 024514 | PKR 229.63 | PKR 45.93/mL | 15% above median |
| PROLOX | Ciprofloxacin | 500 mg/5 mL | Oral suspension | 30ml | 098621 | PKR 295.46 | PKR 9.85/mL | No comparator |
| PROLOX | Ciprofloxacin | 250 mg/5 mL | Oral suspension | 60ml | 098622 | PKR 295.46 | PKR 4.92/mL | 18% above median |
| PROLOX | Ciprofloxacin | 250 mg/5 mL | Oral suspension | 120ml | 098622 | PKR 443.18 | PKR 3.69/mL | 20% below median |
| PROLOX | Ciprofloxacin | 125 mg/5 mL | Oral suspension | 60ml | 098623 | PKR 166.20 | PKR 2.77/mL | 13% below median |
| PROLOX | Ciprofloxacin | 125 mg/5 mL | Oral suspension | 120ml | 098623 | PKR 249.30 | PKR 2.08/mL | 35% below median |
| PROSOTEC | Misoprostol | 100 mcg | Tablet | 10's | 058355 | PKR 110.80 | PKR 11.08/tablet | 12% below median |
| PROSOTEC | Misoprostol | 200 mcg | Tablet | 10's | 058356 | PKR 209.39 | PKR 20.94/tablet | Near median |
| REVOBAN | Rivaroxaban | 10 mg | Tablet | 30's | 080611 | PKR 16,228.33 | PKR 540.94/tablet | Near median |
| REVOBAN | Rivaroxaban | 10 mg | Tablet | 10's | 080611 | PKR 5,522.61 | PKR 552.26/tablet | Near median |
| REVOBAN | Rivaroxaban | 15 mg | Tablet | 7's | 085641 | PKR 5,196.51 | PKR 742.36/tablet | 5% above median |
| REVOBAN | Rivaroxaban | 15 mg | Tablet | 10's | 085641 | PKR 7,050.15 | PKR 705.02/tablet | Near median |
| REVOBAN | Rivaroxaban | 15 mg | Tablet | 14's | 085641 | PKR 9,871.52 | PKR 705.11/tablet | Near median |
| REVOBAN | Rivaroxaban | 20 mg | Tablet | 7's | 085642 | PKR 6,576.18 | PKR 939.45/tablet | 5% above median |
| REVOBAN | Rivaroxaban | 20 mg | Tablet | 10's | 085642 | PKR 8,926.22 | PKR 892.62/tablet | Near median |
| REVOBAN | Rivaroxaban | 20 mg | Tablet | 14's | 085642 | PKR 12,496.18 | PKR 892.58/tablet | Near median |
| REVOBAN | Rivaroxaban | 2.5 mg | Tablet | 7's | 089381 | PKR 1,419.27 | PKR 202.75/tablet | Near median |
MedInfoBase company-intelligence methodology
This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.
Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.
Cite this record
Manufacturer recordRecords change over time. Please cite the access date so readers can locate the version you used.